Women with polyendocrine metabolic ovarian syndrome (PMOS) should be offered an annual review to monitor their symptoms, treatment, and long-term health risks, according to a new draft guideline from the National Institute for Health and Care Excellence (NICE). The updated framework, which rebrands the condition formerly known as polycystic ovary syndrome (PCOS), aims to standardize care and improve diagnostic consistency for a condition affecting approximately one in eight women.
Why the name change to PMOS matters
The transition from PCOS to PMOS follows a 14-year global effort to better represent the clinical reality of the condition. According to NICE, the new name—polyendocrine metabolic ovarian syndrome—more accurately reflects the broad hormonal, metabolic, and reproductive pathways involved. Experts hope this shift will reduce the historical trend of missed diagnoses and inadequate treatment that often left patients without timely support.
PMOS is a lifelong condition. While often associated with reproductive years, the new guidance explicitly states that the condition should not be discounted in women who have been through menopause.
What is included in the annual review?
NICE recommends that patients with a PMOS diagnosis be offered an annual assessment to track the progression of the syndrome. This review is designed to monitor several key areas:
- Symptom progression: Tracking menstrual irregularities and physical symptoms like excess hair growth.
- Medication management: Assessing the ongoing efficacy and side effects of current prescriptions.
- Long-term health risks: Screening for associated conditions including Type 2 diabetes, cardiovascular disease, sleep apnoea, and fatty liver disease.
The guidelines emphasize that mental health, including anxiety and depression, must be evaluated independently of a patient’s weight. NICE reports that these mental health impacts are common across all age groups and should not be dismissed by healthcare providers.
How is the diagnostic process changing?
The draft guidance calls for a more proactive approach to diagnosis. Any individual with irregular or absent menstrual cycles and symptoms of excessive levels of testosterone should be investigated for PMOS, according to the institute. Furthermore, the guidelines advise clinicians to consider ethnic background during assessment, noting that PMOS may be more prevalent in women of Black, Asian, and Mixed ethnicity.
Support for fertility and pregnancy planning
For those planning a pregnancy, the guidance provides structured advice on lifestyle factors including diet, nutrition, exercise, sleep, and mental health. When natural conception is not achieved, the document recommends that IVF should be offered to patients who meet the access criteria. This provides a clearer pathway for those seeking fertility treatment, ensuring that PMOS-related complications are addressed within the standard clinical framework.
What happens next in the guideline process?
The current document is a draft, and NICE is actively seeking feedback from the public, patients, and healthcare professionals. The consultation period runs from 1 July to 11 August 2026. Following this review period, the final clinical guideline is scheduled for publication in December 2026.
If you are a patient or a healthcare provider, you can review the full draft and contribute to the consultation process via the official NICE website.
Frequently Asked Questions (FAQ)
What is the main difference between PCOS and PMOS?
They are the same condition. The name change to PMOS was adopted to better reflect the broad hormonal, metabolic, and reproductive pathways of the condition.
Should I still be monitored for PMOS after menopause?
Yes. According to the new NICE guidance, PMOS should not be discounted in women who have been through menopause, as the condition is lifelong and continues to carry metabolic and health risks.
How can I participate in the current consultation?
The public consultation is open until 11 August 2026. NICE encourages patients and professionals to provide feedback through their official portal to help shape the final version of the guidelines.
Have you or a loved one navigated the diagnostic process for PMOS? Share your experiences in the comments below or subscribe to our health newsletter for the latest updates on medical guidelines and patient care.
